Kazia Therapeutics Limited American Depositary Shares closed at $6.95 on Nov 12, down 6.46%, 58.9% below its 52-week closing high. Volume of 166.5K shares was 0.90× its 20-day average (close to normal).
Split-adjusted performance: +2.4% over one month, -49.7% over six months, -9.3% over one year.
Short interest was 1.4M shares at the Oct 30 settlement, up 10.5% from the prior report (7.9 days to cover).
No reported quarters with price history yet.
Percentile among 417 companies (100 = best)
Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| KZIAKazia Therapeutics Limited | $6.95 | −6.46% | −49.7% | — | — | — | $108.1M | |
| MREOMereo BioPharma Group | $0.3050 | −0.52% | +24.0% | — | — | — | $48.7M | Compare |
| BCYCBicycle Therapeutics | $3.45 | −6.50% | −26.1% | +190.2% | −30.8% | — | $241.8M | Compare |
| AMRNAmarin | $11.67 | −0.34% | −21.0% | −20.4% | 0.6% | — | $490.6M | Compare |
| QNRXQuoin Pharmaceuticals | $3.75 | −0.27% | −35.5% | — | — | — | $18.0M | Compare |
| AKTXAkari Therapeutics plc ADR (0.01 USD) | $6.51 | −12.62% | +75.9% | — | — | — | $14.9M | Compare |
| CMMBChemomab Therapeutics Ltd. American Depositary Share | $1.40 | +3.70% | −17.6% | — | — | — | $11.3M | Compare |
| SLNSilence Therapeutics Plc American Depository Share | $19.80 | +0.15% | +177.7% | — | — | — | $1.23B | Compare |
| CMPSCOMPASS Pathways Plc American Depository Shares | $9.12 | −1.94% | −14.1% | — | — | — | $1.29B | Compare |
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
